The pathogenic mechanisms of ABHD16A-associated HSP are yet to be fully revealed; however, given the interplay of the two lipases along the ABHD16A-ABHD12 axis, normalization of low LPS level can be implemented in treating ABHD16A-associated HSP using selective ABHD12 inhibitors. Here, ABHD12 is linked to hereditary spastic paraplegia.